Cell Source, Inc. (CLCS)
USD 0.36
(28.5%)
USD 0.36
(28.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.23 Million USD | 20.18% |
| 2022 | 7.68 Million USD | 20.47% |
| 2021 | 6.37 Million USD | 39.81% |
| 2020 | 4.56 Million USD | 77.44% |
| 2019 | 2.57 Million USD | -3.15% |
| 2018 | 2.65 Million USD | 36.1% |
| 2017 | 1.95 Million USD | -36.77% |
| 2016 | 3.08 Million USD | 144.93% |
| 2015 | 1.25 Million USD | 1463.84% |
| 2014 | 80.52 Thousand USD | 531.3% |
| 2013 | -18.66 Thousand USD | 15.34% |
| 2012 | -22.05 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 9.3 Million USD | 0.74% |
| 2024 Q2 | 9.91 Million USD | 6.63% |
| 2023 Q4 | 9.23 Million USD | -2.53% |
| 2023 Q2 | 9.43 Million USD | 11.87% |
| 2023 Q1 | 8.43 Million USD | 9.78% |
| 2023 Q3 | 9.47 Million USD | 0.39% |
| 2023 FY | 9.23 Million USD | 20.18% |
| 2022 Q2 | 6.2 Million USD | 3.32% |
| 2022 Q3 | 7.11 Million USD | 14.7% |
| 2022 FY | 7.68 Million USD | 20.47% |
| 2022 Q1 | 6 Million USD | -5.79% |
| 2022 Q4 | 7.68 Million USD | 7.9% |
| 2021 Q4 | 6.37 Million USD | -0.79% |
| 2021 Q3 | 6.42 Million USD | -5.37% |
| 2021 Q2 | 6.79 Million USD | 17.19% |
| 2021 FY | 6.37 Million USD | 39.81% |
| 2021 Q1 | 5.79 Million USD | 27.08% |
| 2020 Q4 | 4.56 Million USD | 19.22% |
| 2020 Q2 | 3.43 Million USD | 12.83% |
| 2020 Q3 | 3.82 Million USD | 11.46% |
| 2020 FY | 4.56 Million USD | 77.44% |
| 2020 Q1 | 3.04 Million USD | 18.33% |
| 2019 Q2 | 1.95 Million USD | -0.74% |
| 2019 FY | 2.57 Million USD | -3.15% |
| 2019 Q1 | 1.96 Million USD | -25.79% |
| 2019 Q4 | 2.57 Million USD | 23.3% |
| 2019 Q3 | 2.08 Million USD | 6.63% |
| 2018 Q3 | 2.96 Million USD | -0.19% |
| 2018 FY | 2.65 Million USD | 36.1% |
| 2018 Q1 | 2.71 Million USD | 39.32% |
| 2018 Q2 | 2.97 Million USD | 9.33% |
| 2018 Q4 | 2.65 Million USD | -10.48% |
| 2017 FY | 1.95 Million USD | -36.77% |
| 2017 Q1 | 2.37 Million USD | -22.99% |
| 2017 Q2 | 2.4 Million USD | 1.34% |
| 2017 Q3 | 2.38 Million USD | -0.95% |
| 2017 Q4 | 1.95 Million USD | -18.19% |
| 2016 Q2 | 2.55 Million USD | 44.83% |
| 2016 FY | 3.08 Million USD | 144.93% |
| 2016 Q3 | 2.87 Million USD | 12.42% |
| 2016 Q4 | 3.08 Million USD | 7.17% |
| 2016 Q1 | 1.76 Million USD | 40.37% |
| 2015 Q3 | 752.85 Thousand USD | 34.79% |
| 2015 Q2 | 558.52 Thousand USD | 275.55% |
| 2015 Q1 | 148.72 Thousand USD | 84.7% |
| 2015 FY | 1.25 Million USD | 1463.84% |
| 2015 Q4 | 1.25 Million USD | 67.26% |
| 2014 Q4 | 80.52 Thousand USD | 177.36% |
| 2014 FY | 80.52 Thousand USD | 531.3% |
| 2014 Q2 | -889.33 Thousand USD | -41225.84% |
| 2014 Q1 | -2152.00 USD | 88.47% |
| 2014 Q3 | -104.08 Thousand USD | 88.3% |
| 2013 Q1 | 161.32 Thousand USD | 0.0% |
| 2013 Q4 | -18.66 Thousand USD | -49.56% |
| 2013 FY | -18.66 Thousand USD | 15.34% |
| 2013 Q3 | -12.48 Thousand USD | 0.0% |
| 2012 FY | -22.05 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 78.426% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1383.372% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 3798.41% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 45337.02% |
| Qrons Inc. | 351.42 Thousand USD | -2526.995% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2926.876% |
| Skye Bioscience, Inc. | -5.72 Million USD | 261.359% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 246.434% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 78.745% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -46368.873% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -63.445% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 704830.611% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 41.433% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -124.184% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2197.373% |
| SQZ Biotechnologies Company | -36.23 Million USD | 125.476% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -311.731% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -895.698% |
| Mesoblast Limited | 55.85 Million USD | 83.473% |
| Marizyme, Inc. | 18.56 Million USD | 50.283% |
| Genus plc | 190.6 Million USD | 95.156% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -312.91% |
| Pharming Group N.V. | 109.8 Million USD | 91.592% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -973.184% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -660.529% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1257.643% |
| ContraFect Corporation | -6.02 Million USD | 253.202% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -6756.833% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -699.008% |
| IMV Inc. | 7.67 Million USD | -20.357% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -67.796% |
| MultiCell Technologies, Inc. | 90.04 USD | -10253088.583% |
| ONE Bio Corp. | 9.04 Million USD | -2.123% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1357.799% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 28.689% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -574.866% |
| Q BioMed Inc. | 4.06 Million USD | -127.388% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 69.785% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -816.128% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1197.715% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 84.752% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -361.739% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 27.912% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2466.504% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -6503.51% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -319.258% |
| GB Sciences, Inc. | 1.74 Million USD | -428.352% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 5123.163% |
| HST Global, Inc. | 96.79 Thousand USD | -9437.85% |
| CSL Limited | 10.52 Billion USD | 99.912% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -4376.823% |
| Halberd Corporation | 144.72 Thousand USD | -6279.151% |
| Enzolytics Inc. | 981.65 Thousand USD | -840.449% |
| Agentix Corp. | 37.63 Thousand USD | -24432.888% |
| Resverlogix Corp. | 6.45 Million USD | -43.109% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1471.583% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.455% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 119.637% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -30.562% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -240.837% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 204.435% |
| AVAX Technologies, Inc. | -5.9 Million USD | 256.389% |
| Zenith Capital Corp. | 10.06 Thousand USD | -91632.621% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.87% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -4506.036% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -286.917% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -5511.833% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 50498.357% |
| Kadimastem Ltd | -253.1 Thousand USD | 3747.53% |
| Helix BioMedix, Inc. | -2.57 Million USD | 459.216% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 54.468% |
| BioStem Technologies, Inc. | 4.47 Million USD | -106.439% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -4487.224% |
| LadRx Corporation | -2.03 Million USD | 553.332% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1353.471% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1353.471% |
| NovAccess Global Inc. | 2.17 Million USD | -323.783% |
| Affymax, Inc. | -5.59 Million USD | 264.945% |
| Itoco Inc. | 228.3 Thousand USD | -3943.701% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -6688.763% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -86.241% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1806.518% |
| CytoDyn Inc. | 20.26 Million USD | 54.437% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1426988.872% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 99707.6% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -19.802% |
| SYBLEU INC | 473.71 Thousand USD | -1848.849% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -107.133% |
| International Stem Cell Corporation | 2.59 Million USD | -256.447% |
| Bioxytran, Inc. | 1.89 Million USD | -386.171% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -14691.744% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -323.31% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -168.84% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -7.938% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1094.912% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 838.558% |
| Neutra Corp. | 52.18 Thousand USD | -17590.174% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 470.911% |
| PureTech Health plc | -167.19 Million USD | 105.522% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 3869.567% |
| IXICO plc | -4.44 Million USD | 307.713% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 30.161% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 83.169% |
| CSL Limited | 10.52 Billion USD | 99.912% |
| Cellectis S.A. | -43.81 Million USD | 121.068% |